Recently, significant and synergistic suppression of tumor growth by the combination of anti-programmed cell death protein 1 antibodies and an FDA-approved receptor tyrosine kinase inhibitor, sunitinib, in a murine model of human HCC was reported [29]. The gene discussed is NTRK1; the disease is neoplasm.